Pfizer has divested a $3.3 billion stake in Haleon, reducing its holding in the British consumer healthcare company.

Haleon separately said on Monday it had agreed to make an off-market purchase of about 230 million pounds ($308.18 million) ...

Pfizer has sold a stake in British consumer healthcare group Haleon worth about $3.26 billion, cutting its shareholding in ...

Pfizer sold 640 million shares in Haleon for 380p each, reducing its holding in the consumer healthcare firm by 7.6% ...

Haleon was formed in 2019 by the merger of the consumer healthcare businesses of GSK and US rival Pfizer, but was spun out ...

Separately, Haleon will also buy around £230 million worth of its shares from Pfizer at the price set in the share offering, ...

Pfizer Inc. announced a further reduction of its stake in Haleon Plc, offering to sell about a 5.9% stake in the UK consumer ...

On completion, Pfizer, the New York-based pharmaceuticals firm, will see its interest in Haleon fall to just over 16% from 22.6% currently. Bloomberg reported that the share sale price is likely to be ...

Pfizer, a New York-based pharmaceuticals firm, sold 640 million Haleon shares at 380 pence per share in a placing run by Goldman Sachs International and BofA Securities as joint global coordinators.

Pfizer (NYSE:PFE) has reduced its ownership in the British consumer healthcare giant Haleon (NYSE:HLN) to 15% from 22.6% by ...

Created in 2022 when GSK and Pfizer span off their three year old consumer brands joint venture, Haleon owns products such as ...